[시장보고서]세계의 경피증 치료제 시장(2024-2028년)

세계의 경피증 치료제 시장(2024-2028년)

Global scleroderma therapeutics market 2024-2028

상품코드 : 1524943 해당 상품은 즉시 배송 가능합니다

리서치사 : TechNavio

발행일 : 2024년 07월

페이지 정보 : 영문 130 Pages

라이선스 & 가격 (부가세 별도)

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

경피증 치료제 시장은 2023-2028년 4억 6,700만 달러 규모, 예측 기간 동안 4.5%의 CAGR로 성장할 것으로 예상됩니다.

본 보고서는 경피증 치료제 시장의 전체 분석, 시장 규모와 예측, 동향, 성장 촉진요인, 과제, 약 25개 벤더를 포함한 벤더 분석 등을 정리하여 전해드립니다.

현재 시장 시나리오, 최신 동향 및 촉진요인, 전체 시장 환경에 대한 최신 분석을 제공합니다. 이 시장은 높은 미충족 의료 수요, 인식 제고에 대한 관심 증가, R&D 활동에 대한 자금 지원 증가에 의해 주도되고 있습니다.

시장 범위
기준 연도	2024
종료 연도	2028
예측 기간	2024-2028
성장 모멘텀	가속
전년 대비 2024년	4.23%
CAGR	4.5%
증분 금액	4억 6,700만 달러

이 보고서는 경피증 치료에서 줄기세포 치료의 도입이 향후 몇 년 동안 경피증 치료제 시장 성장을 견인할 주요 요인 중 하나라고 분석했습니다. 또한, 새로운 치료법의 출현과 제휴 및 전략적 제휴도 시장의 큰 수요로 이어질 것으로 보입니다.

지역별 세분화
지역별 비교
북미 : 시장 규모와 예측 2023-2028
유럽 : 시장 규모와 예측 2023-2028
아시아 : 시장 규모와 예측 2023-2028
세계 기타 지역 : 시장 규모와 예측 2023-2028
캐나다 : 시장 규모와 예측 2023-2028
미국 : 시장 규모와 예측 2023-2028
덴마크 : 시장 규모와 예측 2023-2028
중국 : 시장 규모와 예측 2023-2028
인도 : 시장 규모와 예측 2023-2028
시장 기회 : 지역 상황별

제9장 촉진요인, 과제, 기회, 억제요인

시장 성장 촉진요인
시장 과제
성장 촉진요인과 과제의 영향
시장 기회·억제요인

제10장 경쟁 상황

개요
경쟁 상황
혼란 상황
업계 리스크

제11장 경쟁 분석

기업 개요
기업의 시장 포지셔닝
Akashi Therapeutics
Argentis Pharmaceuticals LLC
Boehringer Ingelheim International GmbH
Bristol Myers Squibb Co.
Castle Creek Biosciences Inc.
Chemomab Therapeutics Ltd.
Corbus Pharmaceuticals Holdings Inc
Emerald Health Pharmaceuticals
F. Hoffmann La Roche Ltd.
Sanofi SA

제12장 부록

ksm

영문 목차

영문목차

The scleroderma therapeutics market is forecasted to grow by USD 467 mn during 2023-2028, accelerating at a CAGR of 4.5% during the forecast period. The report on the scleroderma therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by high unmet medical needs, rising focus on awareness-raising initiatives, and increased funding for r and d activities.

Technavio's scleroderma therapeutics market is segmented as below:

Market Scope
Base Year	2024
End Year	2028
Series Year	2024-2028
Growth Momentum	Accelerate
YOY 2024	4.23%
CAGR	4.5%
Incremental Value	$467mn

By Disease Type

Localized scleroderma
Systemic scleroderma

By Geographical Landscape

North America
Europe
Asia
Rest of World (ROW)

This study identifies the introduction of stem cell therapy in scleroderma treatment as one of the prime reasons driving the scleroderma therapeutics market growth during the next few years. Also, advent of novel therapies and partnerships and strategic alliances will lead to sizable demand in the market.

The report on the scleroderma therapeutics market covers the following areas:

Scleroderma therapeutics market sizing
Scleroderma therapeutics market forecast
Scleroderma therapeutics market industry analysis

The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading scleroderma therapeutics market vendors that include AbbVie Inc., Akashi Therapeutics, Amneal Pharmaceuticals Inc., ANTARES PHARMA INC., Argentis Pharmaceuticals LLC, AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol Myers Squibb Co., Castle Creek Biosciences Inc., Chemomab Therapeutics Ltd., Corbus Pharmaceuticals Holdings Inc, Cumberland Pharmaceuticals Inc., Emerald Health Pharmaceuticals, F. Hoffmann La Roche Ltd., Medexus Pharmaceuticals Inc., Novartis AG, Pfizer Inc., Sanofi SA, and The Procter and Gamble Co.. Also, the scleroderma therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

1 Executive Summary

1.1 Market overview
- Executive Summary - Chart on Market Overview
- Executive Summary - Data Table on Market Overview
- Executive Summary - Chart on Global Market Characteristics
- Executive Summary - Chart on Market By Geographical Landscape
- Executive Summary - Chart on Market Segmentation by Disease Type
- Executive Summary - Chart on Incremental Growth
- Executive Summary - Data Table on Incremental Growth
- Executive Summary - Chart on Company Market Positioning

2 Market Landscape

2.1 Market ecosystem
- Parent Market
- Data Table on - Parent Market
2.2 Market characteristics
- Market characteristics analysis
2.3 Value chain analysis
- Value Chain Analysis

3 Market Sizing

3.1 Market definition
- Offerings of companies included in the market definition
3.2 Market segment analysis
- Market segments
3.3 Market size 2023
3.4 Market outlook: Forecast for 2023-2028
- Chart on Global - Market size and forecast 2023-2028 ($ million)
- Data Table on Global - Market size and forecast 2023-2028 ($ million)
- Chart on Global Market: Year-over-year growth 2023-2028 (%)
- Data Table on Global Market: Year-over-year growth 2023-2028 (%)

4 Historic Market Size

4.1 Global Scleroderma Therapeutics Market 2018 - 2022
- Historic Market Size - Data Table on Global Scleroderma Therapeutics Market 2018 - 2022 ($ million)
4.2 Disease Type segment analysis 2018 - 2022
- Historic Market Size - Disease Type Segment 2018 - 2022 ($ million)
4.3 Geography segment analysis 2018 - 2022
- Historic Market Size - Geography Segment 2018 - 2022 ($ million)
4.4 Country segment analysis 2018 - 2022
- Historic Market Size - Country Segment 2018 - 2022 ($ million)

5 Five Forces Analysis

5.1 Five forces summary
- Five forces analysis - Comparison between 2023 and 2028
5.2 Bargaining power of buyers
- Bargaining power of buyers - Impact of key factors 2023 and 2028
5.3 Bargaining power of suppliers
- Bargaining power of suppliers - Impact of key factors in 2023 and 2028
5.4 Threat of new entrants
- Threat of new entrants - Impact of key factors in 2023 and 2028
5.5 Threat of substitutes
- Threat of substitutes - Impact of key factors in 2023 and 2028
5.6 Threat of rivalry
- Threat of rivalry - Impact of key factors in 2023 and 2028
5.7 Market condition
- Chart on Market condition - Five forces 2023 and 2028

6 Market Segmentation by Disease Type

6.1 Market segments
- Chart on Disease Type - Market share 2023-2028 (%)
- Data Table on Disease Type - Market share 2023-2028 (%)
6.2 Comparison by Disease Type
- Chart on Comparison by Disease Type
- Data Table on Comparison by Disease Type
6.3 Localized scleroderma - Market size and forecast 2023-2028
- Chart on Localized scleroderma - Market size and forecast 2023-2028 ($ million)
- Data Table on Localized scleroderma - Market size and forecast 2023-2028 ($ million)
- Chart on Localized scleroderma - Year-over-year growth 2023-2028 (%)
- Data Table on Localized scleroderma - Year-over-year growth 2023-2028 (%)
6.4 Systemic scleroderma - Market size and forecast 2023-2028
- Chart on Systemic scleroderma - Market size and forecast 2023-2028 ($ million)
- Data Table on Systemic scleroderma - Market size and forecast 2023-2028 ($ million)
- Chart on Systemic scleroderma - Year-over-year growth 2023-2028 (%)
- Data Table on Systemic scleroderma - Year-over-year growth 2023-2028 (%)
6.5 Market opportunity by Disease Type
- Market opportunity by Disease Type ($ million)
- Data Table on Market opportunity by Disease Type ($ million)

7 Customer Landscape

7.1 Customer landscape overview
- Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

8 Geographic Landscape

8.1 Geographic segmentation
- Chart on Market share By Geographical Landscape 2023-2028 (%)
- Data Table on Market share By Geographical Landscape 2023-2028 (%)
8.2 Geographic comparison
- Chart on Geographic comparison
- Data Table on Geographic comparison
8.3 North America - Market size and forecast 2023-2028
- Chart on North America - Market size and forecast 2023-2028 ($ million)
- Data Table on North America - Market size and forecast 2023-2028 ($ million)
- Chart on North America - Year-over-year growth 2023-2028 (%)
- Data Table on North America - Year-over-year growth 2023-2028 (%)
8.4 Europe - Market size and forecast 2023-2028
- Chart on Europe - Market size and forecast 2023-2028 ($ million)
- Data Table on Europe - Market size and forecast 2023-2028 ($ million)
- Chart on Europe - Year-over-year growth 2023-2028 (%)
- Data Table on Europe - Year-over-year growth 2023-2028 (%)
8.5 Asia - Market size and forecast 2023-2028
- Chart on Asia - Market size and forecast 2023-2028 ($ million)
- Data Table on Asia - Market size and forecast 2023-2028 ($ million)
- Chart on Asia - Year-over-year growth 2023-2028 (%)
- Data Table on Asia - Year-over-year growth 2023-2028 (%)
8.6 Rest of World (ROW) - Market size and forecast 2023-2028
- Chart on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Data Table on Rest of World (ROW) - Market size and forecast 2023-2028 ($ million)
- Chart on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
- Data Table on Rest of World (ROW) - Year-over-year growth 2023-2028 (%)
8.7 Canada - Market size and forecast 2023-2028
- Chart on Canada - Market size and forecast 2023-2028 ($ million)
- Data Table on Canada - Market size and forecast 2023-2028 ($ million)
- Chart on Canada - Year-over-year growth 2023-2028 (%)
- Data Table on Canada - Year-over-year growth 2023-2028 (%)
8.8 US - Market size and forecast 2023-2028
- Chart on US - Market size and forecast 2023-2028 ($ million)
- Data Table on US - Market size and forecast 2023-2028 ($ million)
- Chart on US - Year-over-year growth 2023-2028 (%)
- Data Table on US - Year-over-year growth 2023-2028 (%)
8.9 Denmark - Market size and forecast 2023-2028
- Chart on Denmark - Market size and forecast 2023-2028 ($ million)
- Data Table on Denmark - Market size and forecast 2023-2028 ($ million)
- Chart on Denmark - Year-over-year growth 2023-2028 (%)
- Data Table on Denmark - Year-over-year growth 2023-2028 (%)
8.10 China - Market size and forecast 2023-2028
- Chart on China - Market size and forecast 2023-2028 ($ million)
- Data Table on China - Market size and forecast 2023-2028 ($ million)
- Chart on China - Year-over-year growth 2023-2028 (%)
- Data Table on China - Year-over-year growth 2023-2028 (%)
8.11 India - Market size and forecast 2023-2028
- Chart on India - Market size and forecast 2023-2028 ($ million)
- Data Table on India - Market size and forecast 2023-2028 ($ million)
- Chart on India - Year-over-year growth 2023-2028 (%)
- Data Table on India - Year-over-year growth 2023-2028 (%)
8.12 Market opportunity By Geographical Landscape
- Market opportunity By Geographical Landscape ($ million)
- Data Tables on Market opportunity By Geographical Landscape ($ million)

9 Drivers, Challenges, and Opportunity/Restraints

9.1 Market drivers
9.2 Market challenges
9.3 Impact of drivers and challenges
- Impact of drivers and challenges in 2023 and 2028
9.4 Market opportunities/restraints

10 Competitive Landscape

10.1 Overview
10.2 Competitive Landscape
- Overview on criticality of inputs and factors of differentiation
10.3 Landscape disruption
- Overview on factors of disruption
10.4 Industry risks
- Impact of key risks on business

11 Competitive Analysis

11.1 Companies profiled
- Companies covered
11.2 Market positioning of companies
- Matrix on companies position and classification
11.3 Akashi Therapeutics
- Akashi Therapeutics - Overview
- Akashi Therapeutics - Product / Service
- Akashi Therapeutics - Key offerings
11.4 Argentis Pharmaceuticals LLC
- Argentis Pharmaceuticals LLC - Overview
- Argentis Pharmaceuticals LLC - Product / Service
- Argentis Pharmaceuticals LLC - Key offerings
11.5 Boehringer Ingelheim International GmbH
- Boehringer Ingelheim International GmbH - Overview
- Boehringer Ingelheim International GmbH - Product / Service
- Boehringer Ingelheim International GmbH - Key news
- Boehringer Ingelheim International GmbH - Key offerings
11.6 Bristol Myers Squibb Co.
- Bristol Myers Squibb Co. - Overview
- Bristol Myers Squibb Co. - Product / Service
- Bristol Myers Squibb Co. - Key news
- Bristol Myers Squibb Co. - Key offerings
11.7 Castle Creek Biosciences Inc.
- Castle Creek Biosciences Inc. - Overview
- Castle Creek Biosciences Inc. - Product / Service
- Castle Creek Biosciences Inc. - Key offerings
11.8 Chemomab Therapeutics Ltd.
- Chemomab Therapeutics Ltd. - Overview
- Chemomab Therapeutics Ltd. - Product / Service
- Chemomab Therapeutics Ltd. - Key offerings
11.9 Corbus Pharmaceuticals Holdings Inc
- Corbus Pharmaceuticals Holdings Inc - Overview
- Corbus Pharmaceuticals Holdings Inc - Product / Service
- Corbus Pharmaceuticals Holdings Inc - Key offerings
11.10 Emerald Health Pharmaceuticals
- Emerald Health Pharmaceuticals - Overview
- Emerald Health Pharmaceuticals - Product / Service
- Emerald Health Pharmaceuticals - Key offerings
11.11 F. Hoffmann La Roche Ltd.
- F. Hoffmann La Roche Ltd. - Overview
- F. Hoffmann La Roche Ltd. - Business segments
- F. Hoffmann La Roche Ltd. - Key news
- F. Hoffmann La Roche Ltd. - Key offerings
- F. Hoffmann La Roche Ltd. - Segment focus
11.12 Sanofi SA
- Sanofi SA - Overview
- Sanofi SA - Business segments
- Sanofi SA - Key news
- Sanofi SA - Key offerings
- Sanofi SA - Segment focus

12 Appendix

12.1 Scope of the report
12.2 Inclusions and exclusions checklist
- Inclusions checklist
- Exclusions checklist
12.3 Currency conversion rates for US$
- Currency conversion rates for US$
12.4 Research methodology
- Research methodology
12.5 Data procurement
- Information sources
12.6 Data validation
- Data validation
12.7 Validation techniques employed for market sizing
- Validation techniques employed for market sizing
12.8 Data synthesis
- Data synthesis
12.9 360 degree market analysis
- 360 degree market analysis
12.10 List of abbreviations
- List of abbreviations

한글목차

목차

제1장 주요 요약

제2장 시장 상황

제3장 시장 규모 평가

제4장 시장 규모 실적

제5장 Five Forces 분석

제6장 시장 세분화 : 질환 유형별

제7장 고객 상황

제8장 지역별 상황